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Purpose: Dysmenorrhea is a common disorder that substantially disrupts the lives of young 
women. The frequency of 14 associated symptoms both within and outside the pelvis was 
determined.
Patients and methods: Symptom questionnaires were completed by 168 women with 
dysmenorrhea, allocated to three groups based on their diagnostic status for endometriosis 
confirmed (Endo+), endometriosis excluded (Endo−), or endometriosis diagnosis unknown 
(No Lap). Those with endometriosis confirmed were further divided into current users (Endo+ 
Hx+) and non-users of hormonal treatments (Endo+ Hx–). Users of hormonal treatments were 
further divided into users (Endo+ Hx+ LIUCD+) and non-users (Endo+ Hx+ LIUCD–) of a 
levonorgestrel-releasing intra-uterine contraceptive device (LIUCD). The frequency and number 
of symptoms within groups and the effect of previous distressing sexual events were sought.
Results: Women with and without endometriosis lesions had similar symptom profiles, with 
a mean of 8.5 symptoms per woman. Only 0.6% of women reported dysmenorrhea alone. The 
presence of stabbing pelvic pains was associated with more severe dysmenorrhea (P=0.006), 
more days per month of dysmenorrhea (P=0.003), more days per month of pelvic pain (P=0.016), 
and a diagnosis of migraine (P=0.054). The symptom profiles of the Endo+ Hx+ and Endo+ 
Hx– groups were similar. A history of distressing sexual events was associated with an increased 
number of pain symptoms (P=0.003).
Conclusion: Additional symptoms are common in women with dysmenorrhea, and do not 
correlate with the presence or absence of endometriosis lesions. Our study supports the role of 
central sensitization in the pain of dysmenorrhea. The presence of stabbing pelvic pains was 
associated with increased severity of dysmenorrhea, days per month of dysmenorrhea, days per 
month of pelvic pain, and a diagnosis of migraine headache. A past history of distressing sexual 
events is associated with an increased number of pain symptoms.
Keywords: dysmenorrhea, endometriosis, headache, bladder pain syndrome, chronic pain, 
pelvic pain, levonorgestrel-releasing intra-uterine device, stabbing pain
Introduction
Dysmenorrhea, the experience of painful menstruation, is common.1 A study of Aus-
tralian girls aged 16–18 years showed that while 93% experienced some pain with 
menstruation, 21% experienced severe pain, frequently associated with disruption of 
life activities and school absence.2 While dysmenorrhea may be present as a sole symp-
tom without evidence of disease, it may also be associated with the medical condition 
endometriosis, or may pre-date chronic pelvic pain.3–6 Endometriosis is associated with 
an average of 11 hours of lost workplace productivity per week,7 and pelvic pain has 
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been estimated to cost the Australian economy over US$6 
billion per year.8 Dysmenorrhea in isolation, whether as a 
symptom of endometriosis or when associated with chronic 
pelvic pain, is clearly a condition with important educational, 
employment, quality of life, financial, and health economic 
implications.
Developing effective clinical guidelines for the manage-
ment of dysmenorrhea, endometriosis, and chronic pelvic 
pain is complicated due to their overlapping symptomatol-
ogy, a lack of biomarkers, and the requirement that women 
undergo laparoscopic surgery to determine whether endome-
triosis lesions are present.9 In addition, confounding factors, 
potentially including a past history of sexually distressing 
events, may modify the pain experience.10
While several studies have linked a laparoscopic diag-
nosis of endometriosis with a wide range of additional 
symptoms at a rate higher than the general population,9,11–15 
few papers have investigated the frequency of these symp-
toms in women presenting with dysmenorrhea in clinical 
practice. In addition, they have not determined whether a 
specific symptom profile is associated with the presence of 
endometriosis lesions.
This study investigates the prevalence of 14 symptoms 
in women with dysmenorrhea who were referred to a pelvic 
pain and endometriosis unit with ready access to laparoscopic 
surgery. It compares the symptom profile of women with and 
without a laparoscopic diagnosis of endometriosis, and the 
severity of symptoms in women with and without a history 
of distressing sexual events. Three specific hypotheses were 
investigated:
1. That the prevalence of additional symptoms is high in 
women with dysmenorrhea,
2. That a specific symptom profile may indicate the presence 
of endometriosis lesions, and
3. That experience of distressing sexual events may alter 
the symptom profile of women with dysmenorrhea.
This study provides an insight into both the pain experience 
and the symptom profile of women presenting to gynecolo-
gists and laparoscopic surgeons in real-life clinical practice.
Patients and methods
study design
This is a cross-sectional analytical study.
Participants
The target population consisted of girls and women over 16 
years of age, with dysmenorrhea rated as more than 3 on a 
0–10 numerical scale, and with sufficient written English 
language skills to complete a symptom questionnaire. All 
participants were given an informed opportunity, to give 
or withhold consent for the use of their de-identified health 
information for research purposes, by marking one of two 
boxes on the questionnaire (see the section “Test methods” 
for details). Figure 1 shows the CONSORT flow diagram 
for study inclusion.
Permission to study the symptoms of those women who 
had indicated their consent on the questionnaire was approved 
by the Royal Adelaide Hospital Ethics Committee, HREC 
Reference No: R20170604. The study was conducted in 
accordance with the Declaration of Helsinki.
Test methods
The symptom questionnaire (displayed in Appendix 1) was 
posted to all new patients (301 women) referred to a pelvic 
pain and endometriosis unit, with ready access to laparo-
scopic surgery for the period January 1, 2015 to June 30, 
2016. The questionnaire was developed by a pain specialist 
gynecologist (SFE) to assist with patient management. It 
was refined over 18 years to ensure ease of use by patients, 
minimize unanswered questions, and facilitate a full clinical 
assessment of relevant symptoms by the clinician.
The dysmenorrhea-associated symptoms investigated 
included stabbing pains in the pelvis, bowel symptoms, food 
intolerances, bladder symptoms, headaches, pain with sexual 
activity, vulval pain, fatigue, poor sleep, nausea, sweating, 
dizziness, anxiety, and low mood. The presence of anxiety or 
low mood was assessed using a Depression Anxiety Stress 
Scale-21 questionnaire.16
Additional questions recorded patient age, parity, use of 
hormonal treatments for menstrual symptoms, days of pain 
per month, duration of dysmenorrhea, and whether there was 
a history of distressing sexual events, including sexual assault.
Six months following the closure of study enrolment, 
notes for each patient were retrieved and reviewed by the 
principal investigator, who was blinded to patient symptoms. 
Each de-identified patient was allocated to groups according 
to whether a diagnosis of endometriosis had been confirmed 
(Endo+), excluded (Endo–), or could not be determined as no 
laparoscopy had been performed (No Lap). Endometriosis was 
considered confirmed when endometriotic lesions had been 
confidently observed during laparoscopy at any time in their 
life, or where endometriomas were confidently visualized on 
ultrasound at the time of clinical assessment. An ultrasound 
diagnosis of endometrioma has known high specificity for 
pathological confirmation at histology.17 Endometriosis was 
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considered as excluded where at least one laparoscopy had 
been performed during their life, and there had never been 
evidence of endometriotic lesions.
statistical analysis
Following consent, the questionnaire was de-identified, each 
subject was allocated a numerical code, and the de-identified 
data were entered into SPSS statistics 23 software (IBM Corp, 
Armonk, NY, USA). Questionnaire data and data analysis 
were undertaken by investigators blinded to endometriosis 
diagnosis. Statistics for each table are based on all cases with 
valid data in the specified range(s) for all variables.
Descriptive statistics included means and SDs for con-
tinuous variables, and counts and percentages for categorical 
variables. Mean and SDs were compared using independent 
samples t-tests and proportions by chi-squared tests. Pre-
dictors of stabbing pain were determined by multivariable 
logistic regression. Differences were considered significant 
at a P-value of <0.05.
Missing data
As questionnaires were completed independently, prior 
to clinic attendance, it was not possible to ensure that all 
questions were completed. Thus, for each symptom, some 
data were missing. The missing data rate for the 14 symp-
toms excluding “pain with intercourse” averaged 1.1% of 
responses. Missing data rate for the symptom “pain with 
intercourse” was 15% of responses, and missing data rate 
regarding history of “distressing sexual events, including 
sexual assault” was 18%.
Figure 1 consort diagram displaying the study selection process and method of group allocation.
Abbreviation: liUcD, a levonorgestrel-releasing intra-uterine device.
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Results
Details of patient numbers overall and in each group are 
provided in Figure 1. Of 301 women who completed the 
questionnaire, informed consent was provided by 255 women 
and declined by 25 women. Twenty-one women neglected to 
complete the request for consent and were deemed to have 
declined. Where the patient was under the age of 18 years, 
inclusion required the presence of a parent during the medical 
consultation to confirm consent.
From this cohort of 255 women, 168 patients suffered dys-
menorrhea. Eighty-seven women were excluded from the study 
as their pain from dysmenorrhea was rated as less than 3 on a 
numerical 0–10 score (n=83), or written English language skills 
were poor (n=4), and consent could not reasonably be obtained.
From this cohort of 168 women, those patients with 
endometriosis confirmed (Endo+, n=101), endometriosis 
excluded (Endo–, n=22), and where a diagnosis could neither 
be confirmed nor excluded (No Lap, n=45), were identified. 
Of those women with endometriosis confirmed, 16% were 
classified as stage 1–2 and 84% were classified as stage 
3–4, using the revised American Society for Reproductive 
Medicine Classification.18
The cohort of 101 women with endometriosis confirmed 
was then divided into those patients using hormonal therapies 
(Endo+ Hx+, n=56) and those patients not using hormonal 
therapies (Endo+ Hx−, n=45). The hormonal therapies 
utilized by participants included the oral contraceptive pill 
(n=33), a levonorgestrel-loaded intra-uterine contraceptive 
device (LIUCD, n=16), an oral contraceptive pill with LIUCD 
in combination (n=3), an etonorgestrel implant (n=6), depot 
medroxyprogesterone acetate (n=1), oral norethisterone 
(n=2), and oral estradiol (n=1).
From the cohort of 56 women with endometriosis con-
firmed who were using hormonal therapies, those women 
currently using hormonal treatments were further divided 
into those women whose hormonal therapy included a 
LIUCD (Endo+ Hx+ LIUCD+, n=17), and those women 
on hormonal therapy that did not include a LIUCD (Endo+ 
Hx+ LIUCD–, n=39).
Results were collated for eight patient groupings:
1. All women with dysmenorrhea (All Dys, n=168)
2. Women with endometriosis confirmed (Endo+, n=101)
3. Women with endometriosis excluded (Endo–, n=22)
4. Women with endometriosis confirmed who were current 
users of hormonal therapy (Endo+ Hx+, n=56)
5. Women with endometriosis confirmed who were non-
users of hormonal therapy (Endo+ Hx–, n=45)
Figure 2 The percentage of women reporting between one and 14 symptoms in 
addition to dysmenorrhea.
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additional symptoms present per woman 
with dysmenorrhea
Figure 2 displays the number of additional symptoms experi-
enced per woman across the whole group with dysmenorrhea. 
Dysmenorrhea was the sole symptom in 0.6% of women, and 
2.4% of women reported that all 14 symptoms were present. 
The mean number of additional symptoms was 8.5.
Demographic, pain, and menstrual data by 
endometriosis diagnosis
Patient groups All Dys, Endo+, Endo–, and No Lap were 
broadly similar with regard to age, age of menarche, age when 
dysmenorrhea commenced, frequency of previous pregnancy, 
and parity (Table 1). The age of participants ranged from 13 
to 50 years with a mean age of 29.2 years (SD 8.4 years). 
Across all women, the mean severity of dysmenorrhea was 
7.9 on a 0–10 numerical scale with an SD of 1.7.
Compared to women without endometriosis (Endo–), 
women with a confirmed diagnosis of endometriosis (Endo+) 
showed no statistically significant differences for severity 
of dysmenorrhea (8.1 vs 8.3, P=0.528), days per month of 
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 dysmenorrhea (8.1 vs 6.1, P=0.235), days per month of pelvic 
pain (18.3 vs 21.1, P=0.177), and parity (38.6% vs 45.5%, 
P=0.588). Table 1 displays the demographic, pain, and men-
strual data for each patient group by endometriosis diagnosis.
Symptom profile by endometriosis 
diagnosis
Table 2 displays the prevalence of each of the following symp-
toms across the four patient groups: stabbing pelvic pains, 
bowel symptoms, food intolerances, bladder symptoms, pain 
with sexual activity, headaches, vulval pain, fatigue, poor 
sleep, nausea, sweating, dizziness, anxiety, and low mood. 
One hundred percent of participants reported dysmenorrhea, 
consistent with the study inclusion criteria.
Table 1 Demographic, pain, and menstrual data by endometriosis diagnosis
General demographics All women with 
dysmenorrhea  
(All Dys)  
(n=168)
No laparoscopy 
(No Lap) (n=45)
Endometriosis 
confirmed  
(Endo+)  
(n=101)
Endometriosis 
excluded  
(Endo−)  
(n=22)
Significance
Endo+ vs
Endo–
(P-value)*
Mean age (sD) 29.2 (8.4) 29.3 (8.3) 29.2 (8.3) 28.8 (9.7) 0.848
Mean age menarche (sD) 12.7 (1.7) 12.7 (2.0) 12.8 (1.7) 12.6 (1.5) 0.753
Previous pregnancy (%) 39.9 40 38.6 45.5 0.553
Parous (%) 32.7 31.8 32.0 38.1 0.588
Menstrual and pain data
severity dysmenorrhea 0–10 scale (sD) 7.9 (1.7) 7.2 (2.0) 8.1 (1.5) 8.3 (1.6) 0.528
age dysmenorrhea began (sD) 16.2 (6.1) 16.7 (6.4) 15.9 (5.8) 16.48 (6.9) 0.699
Dysmenorrhea days per month (sD) 7.2 (6.0) 5.7 (5.1) 8.1 (6.6) 6.1 (4.0) 0.235
Days per month pelvic pain (sD) 17.9 (9.1) 15.5 (9.2) 18.3 (9.1) 21.1 (8.0) 0.177
Notes: all Dys, all women with dysmenorrhea, chi-squared test; endo+, women with endometriosis confirmed; Endo–, women with endometriosis excluded; No Lap, 
women where no laparoscopy had been performed; *comparison of mean by independent samples t-test.
Table 2 symptom prevalence by endometriosis diagnosis
Symptom All women with 
dysmenorrhea  
(All Dys) (n=168)
No laparoscopy 
(No Lap) (n=45)
Endometriosis 
confirmed (Endo+) 
(n=101)
Endometriosis 
excluded (Endo−) 
(n=22)
Significance 
Endo+ vs endo– 
(P-value)*
Dysmenorrhea (%) 100 100 100 100
stabbing pain (%) 63.9 47.7 69 72.7 0.731
Bowel problems (%) 47.3 40.9 49.5 50.0 0.966
Food intolerances (%) 66.1 62.8 65 77.3 0.267
Bladder problems (%) 23.2 18.2 20 50 0.005
headaches (%) 56 46.7 58.4 63.6 0.651
sexual pain (%) 37.8 36.1 38.2 38.9 0.956
Vulval pain (%) 38.6 35.9 41.2 31.8 0.415
Fatigue (%) 74.4 68.9 77.2 72.7 0.652
Poor sleep (%) 57.7 57.8 58.4 54.5 0.739
nausea (%) 49.1 42.9 48 66.7 0.12
sweating (%) 33.9 28.9 33.7 45.5 0.296
Dizziness/faint (%) 58.9 48.9 62.4 63.6 0.912
anxiety (%) 58.7 61.4 56.4 63.6 0.536
low mood (%) 57.7 60 58.4 50 0.47
Notes: all Dys, all women with dysmenorrhea; endo+, women with endometriosis confirmed; Endo–, women with endometriosis excluded; No Lap, women where no 
laparoscopy had been performed; *chi-squared tests.
The frequency of each symptom was compared in women 
with endometriosis confirmed (Endo+) and women with 
endometriosis excluded (Endo–). The frequency of individual 
symptoms was similar in both groups, apart from a signifi-
cantly higher frequency of bladder symptoms (P=0.005) in 
women with endometriosis excluded. Figure 3 displays the 
prevalence of each symptom across the four patient groups.
Demographic, pain, and menstrual data 
by use of hormonal therapies in women 
with confirmed endometriosis
Women with confirmed endometriosis were more frequent 
users of a LIUCD (15.8% vs 7.1%, P=0.106), but this dif-
ference was not statistically significant. Table 3 displays the 
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Figure 3 The frequency of specific symptoms by endometriosis diagnosis.
Notes: all Dys, all women with dysmenorrhea; endo+, women with endometriosis confirmed; Endo−, women with endometriosis excluded; no lap, women where no 
laparoscopy had been performed.
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Table 3 Demographic, pain, and menstrual data in women with endometriosis according to use or non-use of hormonal therapies and 
use or non-use of a levonorgestrel-releasing intra-uterine device
General demographics Endo+ 
Hx+ 
(n=56)
Endo+ 
Hx– 
(n=45)
Significance 
Endo+ Hx+ 
vs Endo+ Hx– 
(P-value)*
Endo+ 
Hx+ 
LIUCD+ 
(n=17)
Endo+ Hx+ 
LIUCD– 
(n=39)
Significance 
Endo+ Hx+ 
LIUCD+ vs Endo+ 
Hx+ LIUCD– 
(P-value)*
Mean age, years (sD) 28.2 (7.9) 30.3 (8.7) 0.221 31.1 (7.0) 27.0 (8.1) 0.073
Mean age at menarche, years (sD) 12.8 (1.8) 12.7 (1.6) 0.888 12.9 (1.6) 12.7 (1.6) 0.658
Previous pregnancy (%) 28.6 51.1 0.021 41.2 23.1 0.168
Parous (%) 22.6 43.2 0.026 35.3 16.7 0.13
Menstrual and pain data
severity on dysmenorrhea 0–10 scale (sD) 8.3 (1.5) 7.8 (1.4) 0.167 8.1 (1.9) 8.311 (1.4) 0.743
age dysmenorrhea began,  years (sD) 14.9 (3.7) 17.2 (7.4) 0.054 14.8 (3.4) 14.9 (3.9) 0.949
Dysmenorrhea days per month (sD) 9.4 (7.5) 6.5 (4.9) 0.037 12.9 (9.1) 8.1 (6.5) 0.05
Pelvic pain days per month (sD) 20.1 (9.2) 16.0 (8.4) 0.027 20.8 (7.6) 19.8 (10.0) 0.714
Notes: endo+ hx+, women with endometriosis confirmed on hormonal therapy; Endo+ hx+ liUcD+, women with endometriosis confirmed using hormonal therapy 
that included a liUcD; endo+ hx+ LIUCD–, women with endometriosis confirmed using hormonal therapy excluding a LIUCD; Endo+ hx−, women with endometriosis 
confirmed on no hormonal therapy; *comparison of mean by independent samples t-test, comparison of proportions by chi-squared tests.
Abbreviation: liUcD, levonorgestrel-releasing intra-uterine contraceptive device.
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demographic, pain, and menstrual data in women with endo-
metriosis according to use or non-use of hormonal therapies 
including a LIUCD.
Compared to women with endometriosis who were 
non-users of hormonal therapy (Endo+ Hx−), women with 
endometriosis who were current users of hormonal therapies 
(Endo+ Hx+) reported significantly more days of dysmen-
orrhea per month (P=0.037), more days of pelvic pain per 
month (P=0.027), were more likely to have had a previous 
pregnancy (P=0.021), and were more likely to be parous 
(P=0.026).
Compared to women with endometriosis using hormonal 
therapies that excluded a LIUCD (Endo+ Hx+ LIUCD–), 
women with endometriosis using hormonal therapies that 
included a LIUCD (Endo+ Hx+ LIUCD+) reported sig-
nificantly more days of dysmenorrhea per month (P=0.05).
Symptom profile by use of hormonal 
therapies in women with confirmed 
endometriosis
A comparison was undertaken between women with endo-
metriosis who used (Endo+ Hx+) or did not use (Endo+ 
Hx−) hormonal therapy, to determine if hormonal treat-
ment was associated with a change in symptoms (Table 4). 
The frequency of individual symptoms was similar in both 
groups apart from an increase in sweating among those not 
receiving hormonal therapy (P=0.009). Figure 4 displays 
the symptom profile in women with endometriosis by use 
of hormonal therapy.
A further comparison was undertaken between women 
with endometriosis using hormonal therapy that included a 
LIUCD (Endo+ Hx+ LIUCD+), and women with endome-
triosis using hormonal therapy without a LIUCD (Endo+ Hx+ 
LIUCD–). Those women using a LIUCD trended to a higher 
frequency of stabbing pains in the pelvis (82.4% vs 63.2%, 
P=0.155) and sweating (58.8% vs 38.5%, P=0.159) than 
those women using hormonal therapies without a LIUCD, 
but these differences were not statistically significant.
Dysmenorrhea and stabbing pelvic pains
One hundred and six of the 166 women (63.9%) who 
answered the question about stabbing pains in the pelvic 
region reported that stabbing pains were present. Based on 
univariate logistic regression, variables associated with stab-
bing pain included: severity of dysmenorrhea (OR =1.60, 
95% CI =1.27–2.01, P<0.001), number of additional symp-
toms (OR =1.26, 95% CI =1.12–1.41, P<0.001), diagnosis 
of migraine (OR =2.30, 95% CI =0.97–5.46, P=0.058), 
number of days per month of dysmenorrhea (OR =1.15, 95% 
CI =1.04–1.28, P=0.007), and number of days per month 
Table 4 symptom prevalence across women with endometriosis, according to use or non-use of hormonal therapies, and use or non-
use of a levonorgestrel-releasing intra-uterine device
Symptom Endo+ Hx+
(n=56)
Endo+ Hx–
(n=45)
Endo+ Hx+
LIUCD+
(n=17)
Endo+ Hx+
LIUCD–
(n=39)
Significance
Endo+ Hx+ 
vs
Endo+ Hx–
(P-value)*
Significance
Endo+ Hx+ LIUCD+ 
vs
Endo+ Hx+ LIUCD–
(P-value)*
Dysmenorrhea (%) 100 100 100 100 1 1
stabbing pain (%) 69.1 68.9 82.4 63.2 0.983 0.155
Bowel problems (%) 48.9 50 47.1 51.3 0.912 0.771
Food intolerances (%) 66.7 63.6 52.9 68.4 0.752 0.270
Bladder problems (%) 20.0 20.0 17.6 21.1 1.000 0.770
headaches (%) 55.6 60.7 64.7 59 0.601 0.686
sexual pain (%) 35.9 40 37.5 41.2 0.693 0.804
Vulval pain (%) 38.6 43.3 35.3 47.2 0.635 0.413
Fatigue (%) 68.9 83.9 88.2 82.1 0.073 0.562
Poor sleep (%) 55.6 60.7 70.6 56.4 0.601 0.318
nausea (%) 50 46.4 58.8 41 0.723 0.219
sweating (%) 20 44.6 58.8 38.5 0.009 0.159
Dizziness/faint (%) 62.2 62.5 52.9 66.7 0.977 0.329
anxiety (%) 57.8 55.4 52.9 56.4 0.807 0.810
low mood (%) 57.8 58.9 64.7 56.4 0.907 0.562
Notes: endo+ hx+, women with endometriosis confirmed on hormonal therapy; Endo+ hx+ liUcD+, women with endometriosis confirmed using hormonal therapy 
that included a liUcD; endo+ hx+ LIUCD–, women with endometriosis confirmed using hormonal therapy excluding a LIUCD; Endo+ hx–, women with endometriosis 
confirmed on no hormonal therapy; * chi-squared tests.
Abbreviation: liUcD, levonorgestrel-releasing intra-uterine contraceptive device.
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of pelvic pain (OR =1.05, 95% CI =1.01–1.08, P=0.017). 
Multivariable logistic regression found that the best joint 
predictors of stabbing pain were the severity of period pain 
(OR =1.71, 95% CI =1.31–2.24, P<0.001), the number 
of additional symptoms (OR =1.30, 95% CI =1.13–1.49, 
P<0.001), and a diagnosis of migraine (OR =4.34, 95% CI 
=1.46–12.87, P=0.008).
Dysmenorrhea and headache
One hundred and twenty-three of the 152 women (80.9%) 
with dysmenorrhea who answered the question “Do you have 
headaches?” reported headache on at least 1 day per month. 
Of these, 43 women (40.2%) reported the presence of head-
ache on 10 or more days per month, and 26 women (21.1%) 
on 15 or more days per month. The average number of days 
of reported headache was 10 days per month.
analysis of symptoms by past history of 
distressing sexual events
Participants were asked whether they had “experienced 
distressing sexual events during their life, including sexual 
Figure 4 The frequency of specific symptoms by use or non-use of hormonal therapies, and use or non-use of a levonorgestrel-releasing intra-uterine device. 
Notes: endo+ hx+, women with endometriosis confirmed using hormonal therapy; Endo+ Hx–, women with endometriosis confirmed not using hormonal therapy; Endo+ 
hx+ liUcD+, women with endometriosis confirmed using hormonal therapy that included a LIUCD; Endo+ hx+ LIUCD–, women with endometriosis confirmed using 
hormonal therapy excluding a liUcD.
Abbreviation: liUcD, levonorgestrel-releasing intra-uterine contraceptive device.
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assault”, with the opportunity to answer “Yes”, “No”, or 
“I prefer not to answer this question”. This question was 
answered by 138 (82.1%) of women, with 23 (16.7%) 
answering “Yes”, and 115 (83.3%) answering “No”. Figure 5 
displays the dysmenorrhea score, days per month of pelvic 
pain, and number of symptoms in women with and without 
a history of distressing sexual events. Women with a history 
of distressing sexual events reported a significantly higher 
number of symptoms (P=0.003) than women without a 
history of these events (Table 5). There was a trend toward 
significance for the days per month of pain (25 vs 20 days, 
P=0.053).
Discussion
Our study has demonstrated four clinical findings. First is 
that additional symptoms are common in women with dys-
menorrhea. Second is that the symptom profile in our study 
was generally independent of the presence or absence of 
endometriosis lesions, and independent of the use or non-use 
of hormonal therapy in those with confirmed endometrio-
sis. Third is that the presence of stabbing pains in women 
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Figure 5 Dysmenorrhea pain score, days per month of pelvic pain, and number of symptoms reported in women with, and without, a history of distressing sexual events.
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with endometriosis is highly associated with the severity of 
dysmenorrhea, days per month of dysmenorrhea, days per 
month of pelvic pain, and diagnosis of migraine headache. 
And finally that a past history of distressing sexual events 
is associated with an increase in the severity and number of 
pain symptoms.
A woman’s experience of dysmenorrhea includes all 
symptoms experienced at menstruation, both pelvic and 
extra-pelvic. A major strength of this study is its symptom-
based applicability to the management of women presenting 
with dysmenorrhea and its associated symptoms, regardless 
of endometriosis status. While our group may represent a 
more complex subset of women with dysmenorrhea than 
is found in the general population, it is likely that they are 
similar to women referred to other gynecologists providing 
care for women with endometriosis and pelvic pain.
The lack of association between pain 
severity, presenting symptom profile and 
the presence of endometriotic lesions
Dysmenorrhea and pelvic pain have traditionally been associ-
ated with the presence of laparoscopically diagnosed endo-
metriosis lesions. While these conditions commonly coexist, 
the relationship between the clinical symptoms with which 
a girl or woman presents to her health practitioner (dysmen-
orrhea) and the medical condition that may or may not be 
found at laparoscopy (endometriosis) remains controversial. 
A literature review by Janssen et al4 considered laparoscopic 
outcomes in adolescent girls aged 10–21 years presenting 
with pain. They found endometriosis lesions to be present 
in 62% of adolescents overall, in 75% of girls with chronic 
pelvic pain resistant to treatment with the oral contraceptive 
pill and anti-inflammatory medications, in 70% of girls with 
dysmenorrhea alone, and in 49% of girls with chronic pelvic 
pain not necessarily resistant to treatment. Additional factors 
affecting the experience of dysmenorrhea appear likely. A 
consensus paper published in 2013 included majority but not 
universal support for a statement describing a “ philosophical 
shift to consideration of endometriosis and pelvic pain as 
a spectrum or continuum of disease”.9 It was recognized 
that this approach would avoid excluding women who lack 
laparoscopic confirmation of a diagnosis of endometriosis, 
yet have similar symptoms and associated diagnostic and 
therapeutic interventions.
Robust evidence demonstrates that the presence of endo-
metriosis lesions does not determine the severity of pelvic 
pain. In 656 women with chronic pelvic pain, Yosef et al 
found significant correlations between the severity of pain 
and the presence of dysmenorrhea, irritable bowel syndrome, 
painful bladder syndrome, pelvic muscle pain, or abdomi-
nal wall pain, but not with the presence of endometriotic 
lesions.19 As-Sanie et al used functional MRI to demonstrate 
that the experience of chronic pain was associated with 
anatomical changes in the brain rather than the presence of 
endometriosis lesions,20 and Vercellini et al confirmed the 
lack of association between the severity of laparoscopically-
staged endometriosis lesions and the severity of pain expe-
rienced.21 With regard to the reduction in quality of life and 
increase in anxiety and depression common in women with 
endometriosis,22 Facchin et al demonstrated that it is the 
presence of pain, rather than the presence of lesions, that is 
of importance.23 Women with asymptomatic endometriosis 
enjoyed the same quality of life and mental health outcomes 
as healthy controls. In our study, women with endometriosis 
excluded had a significantly higher frequency of blad-
der symptoms (50% vs 20%, P=0.005) than women with 
endometriosis confirmed. This may reflect the presence of 
coexisting painful bladder syndrome, a common cause of 
pelvic pain that clusters with other pelvic pain diagnoses.24 
By choosing to study women presenting with dysmenorrhea, 
rather than purely those with confirmed endometriosis, our 
findings further separate the pain of dysmenorrhea and the 
presence of endometriosis lesions. Our study also provides 
clinically relevant information to assist the management 
of women with dysmenorrhea where their endometriosis 
status is unknown.
Table 5 Dysmenorrhea score, days per month of pelvic pain, and number of symptoms in women with, and without, a history of 
distressing sexual events
Past history of distressing  
sexual events
No past history of distressing  
sexual events
Significance*
N Mean SD N Mean SD
Dysmenorrhea pain score 20 8.4 1.8 103 7.8 1.6 0.112
Pelvic pain days per month 23 22.0 8.4 112 18.1 9.0 0.055
number of symptoms 23 10.5 2.6 115 8.3 3.2 0.003
Note: *independent samples t-tests.
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The association between pain symptoms 
and central sensitization
Two mechanisms consistently implicated with both the 
development of endometriotic lesions25 and a range of 
persistent visceral pain conditions26 are inflammation and 
activation of the innate immune system resulting in central 
pain sensitization. Inflammation elicits pain via inflamma-
tory mediators and peripheral sensitization of nociceptors.27 
Central sensitization may arise following continuous or 
recurrent nociceptive input from the periphery, resulting in 
enhanced excitability of spinal projection neurons in the spi-
nal cord and central nociceptor terminals within the brain.28 
Enhanced neurotransmission with long lasting molecular 
changes in both the spinal cord and brain may result in 
pain perception that no longer reflects, and is independent 
of, peripheral pain nociceptive signaling.26 Altered central 
processing of nociception in women with dysmenorrhea, 
both during menses and on pain-free days, as measured by 
serum cortisol, response to thermal stimuli, and functional 
MRI investigation, has been demonstrated by Vincent et al, 
Arendt-Nielssen et al, and Iacovides et al,29–31 with literature 
review by Payne et al.32 Central sensitization has the potential 
to affect both pelvic and extra-pelvic pain symptomatology.
With regard to pelvic symptoms, there is ample evidence 
for the convergence of sensory information from discrete 
pelvic organs of the gastrointestinal or genitourinary tract 
in the dorsal root ganglia, spinal cord, and brain,33,34 result-
ing in viscero-visceral hyperalgesia and the experience of 
multiple pain symptoms across pelvic organs. The women in 
our study demonstrated a high frequency of bowel (47.3%) 
and bladder (23.2%) symptoms. Both irritable bowel syn-
drome and painful bladder syndrome cluster in women with 
pelvic pain, and are associated with central sensitization and 
inflammation13,24,35
There is also evidence for the convergence of sensory 
information from visceral and somatic pelvic structures in the 
dorsal horn of the spinal cord. This results in visceral-somatic 
hyperalgesia and the experience of reflex muscle contraction 
and spasm associated with visceral pain as a manifestation 
of central sensitization.36–38 Our study demonstrated a high 
frequency of stabbing pain (63.9%), a symptom associated 
with musculoskeletal pain39 in women with dysmenorrhea. 
The presence of stabbing pelvic pain was highly associated 
with the severity of dysmenorrhea, days per month of dys-
menorrhea, and days per month of pelvic pain.
With regard to extra-pelvic symptoms, central pain 
mechanisms have been implicated in the experience of 
fatigue, poor sleep, fibromyalgia, and headache.40 The high 
frequency of chronic headache in our study is striking. 
About 80.9% of participants reported headache, with 21.1% 
reporting headaches on 15 or more days per month. In com-
parison, a population-based study in Italy found 42.8% of 
people reported headache in the previous year, and only 3.4% 
reported headache on 15 or more days per month.41 These 
findings are consistent with growing evidence for the role of 
central sensitization20 and extra-pelvic symptoms in the lived 
pain experience of women with dysmenorrhea.
endometriosis as a common comorbidity 
of pelvic pain syndrome (PPs)
Endometriosis and dysmenorrhea frequently coexist.4 
However, the high frequency of symptoms in our study, 
both within and outside the pelvis, regardless of endome-
triosis status, supports the view that endometriosis and 
pain may be associated, rather than etiologically linked, 
conditions. They may share a similar underlying mecha-
nism, yet represent distinct clinical entities within a larger 
syndrome of associated symptoms and conditions. Both 
endometriosis and dysmenorrhea would then be common, 
but non-essential features of female PPS, much as polycys-
tic ovaries are common, but non-essential, features of the 
systemic metabolic disorder, polycystic ovarian syndrome 
(PCOS).42
Further support for considering endometriosis and dys-
menorrhea as common features within female PPS comes 
from Clemens et al, who found similar pain symptoms in 
male PPS, where endometriosis and dysmenorrhea do not 
occur.43 Sutcliffe et al described similar clinical symptoms 
during pelvic pain flares in men and women with urologically 
based PPS, although flares were more frequent and of longer 
duration in women.44
The association between pain symptoms 
and use of hormonal therapies including a 
liUcD
A LIUCD is a long-acting, reversible contraceptive that 
releases 20 µg of levonorgestrel per day over 5 years of use. 
It offers effective contraception, reduced menstrual blood 
flow, reduced dysmenorrhea, and high levels of patient 
satisfaction in the general population,45,46 or women with 
adenomyosis,47 particularly in those women who have cho-
sen to continue using a LIUCD for more than 12 months.48 
However, a proportion of women request removal of the 
device in the first year of use, with the commonest reasons 
for premature device removal being pain and irregular bleed-
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ing.49 In women with endometriosis, use of a LIUCD has the 
added benefit of reducing the recurrence of endometriosis 
lesions following laparoscopic surgery.50 However, despite 
these known benefits of a LIUCD, Lockhat et al51 found 
that only 68% of women continued to use a LIUCD at 12 
months post-insertion, with 11.8% of women requesting 
removal of the LIUCD due to “abdominal pain”. Our study 
found that women with endometriosis using hormonal thera-
pies reported significantly more days per month of pelvic 
pain, and that those using a LIUCD had a higher, but not 
statistically significant, increase in stabbing pains (82.4% 
vs 63.2%, P=0.155) when compared with non-users of 
hormonal therapies. This may reflect the referral of women 
with pain for whom these therapies had been tried but found 
unsuccessful, potentially in women with more severe central 
pain sensitization. Research to review whether the presence 
of stabbing pains may indicate a subgroup of women more 
likely to report persistent or unresolved pain following 
LIUCD insertion should be considered. Our study did not 
include sufficient patients to investigate the relative benefits 
of individual oral hormonal therapies or regimes, as has been 
proposed in other studies.52,53
The effect of previously distressing sexual 
events on symptom severity
Our finding that those women who reported a history of 
distressing sexual events suffered more pelvic pain supports 
similar findings by Yosef et al.19 Their study found that a 
history of sexual abuse was significantly associated with 
increased severity of pelvic pain. Ballina et al described 
enhanced recovery and reduced pain severity following 
sexual assault in women with opioid receptor polymorphisms, 
further linking pain mechanisms to pain severity.54 Schliep 
et al found no increase in the frequency of endometriosis in 
women with prior history of sexual assault.10
Despite our finding that a history of distressing sexual 
events was associated with more severe pain, the majority 
of our patients reported no sexual assault. The frequency of 
distressing sexual events (16.7%) is consistent with popula-
tion data described in the Australian Bureau of Statistics 
Personal Safety Survey55 (2016), where 18% of Australian 
women had experienced sexual violence since the age of 15 
years. With a 15% missing data rate for this question in the 
present study, it is possible that adverse sexual events were 
under-reported in our sample. However, by analyzing only 
those women who reported either “yes” or “no”, the potential 
for error has been minimized.
Translational significance for clinical 
practice
Our study investigated 14 dysmenorrhea-associated symptoms 
in a group of women presenting to a gynecology clinic with par-
ticular interest in endometriosis, dysmenorrhea, and pelvic pain. 
This has wide-ranging clinical applications. Firstly, our study 
shows that the full assessment of a woman with dysmenorrhea 
should proceed with the expectation that multiple symptoms, 
both within and outside the pelvis, are likely to be present. 
Secondly, we found that the presenting symptom profile was an 
unreliable indicator of the presence of endometriosis, as similar 
pain profiles were found in women both with and without endo-
metriosis lesions. Thirdly, our findings have implications for the 
training of health practitioners. The wide range of symptoms 
included within dysmenorrhea-associated PPS extends beyond 
the traditional teaching of individual medical and allied health 
care domains. There are consequently similarities between the 
changing management of PPS and the evolved management 
of PCOS. Comprehensive care of the pelvic and extra-pelvic 
symptoms of PCOS has moved beyond management of ovarian 
cysts to include the assessment of blood lipid and sugar profiles, 
the management of hirsuitism and acne, and lifestyle advice to 
manage obesity and reduce inactivity.
The high frequency of the covarying of migraine, stabbing 
pain, and dysmenorrhea supports further research investigat-
ing a potential common mechanism involving acquired cen-
tral pain sensitization for these conditions. A pilot study by 
Sator-Katzenschlager et al56 using amitriptyline or gabapentin 
in 56 women with chronic pelvic pain found a reduction in 
pain among both treatment groups. If proven, this would sup-
port the use of therapeutic interventions directed at central 
sensitization with effects on both pelvic and extra-pelvic 
symptoms in women with dysmenorrhea.
Conclusion
This study aims to extend our knowledge in an area that has 
been under-researched with regard to its impact on the well-
being of women, their families, and our society: the lived 
experience of women with dysmenorrhea.
While the lack of a control group in this study limits our 
ability to make firm conclusions, our findings indicate that 
additional symptoms are common in these women, and that 
the presence of endometriosis lesions cannot reliably be 
predicted by the presenting symptom profile. Of the symp-
toms investigated, the presence of stabbing pelvic pains and 
migraine headaches were most closely correlated with the 
severity of dysmenorrhea. The presence of both pelvic and 
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extra-pelvic symptoms is consistent with central sensitiza-
tion as a component mechanism in female PPS. A history of 
distressing sexual events was associated with an increased 
number of pain symptoms, but was not more common than 
in the general population.
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